Double-Targeted CAR-T therapy aims to outsmart relapse in tough lymphoma
NCT ID NCT07461831
First seen Mar 11, 2026 · Last updated May 14, 2026 · Updated 9 times
Summary
This study tests a new CAR-T cell therapy that targets two proteins (CD19 and CD22) on cancer cells to treat large B-cell lymphoma that has come back or not responded to standard treatments. The goal is to see if this dual-targeting approach can improve response rates and reduce the chance of relapse. About 100 participants aged 14 to 85 with measurable disease will receive the therapy and be monitored for safety and effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LARGE B-CELL LYMPHOMA (LBCL) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Tongren Hospital, Capital Medical University
Beijing, Beijing Municipality, 100730, China
Conditions
Explore the condition pages connected to this study.